View Post

Practicing Outside the Pharma Box in Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Dawn Fallik From: onclive.com When Martine Piccart, MD, PhD, was a child, she sometimes watched her father, a gynecologist, talk to his patients. She remembers his respect for them and their families and the way he communicated, focusing on the positive but not shying away from delivering bad news. “He always took the time to explain in detail not …

View Post

Gut microbe may promote breast cancers

In Clinical Trials by Barbara Jacoby

Source: Johns Hopkins Medicine From: eurekalert.org Short-term exposure to B. fragilis toxin leaves lasting impression in cells, increasing the risk for cancer A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns …

View Post

Quantitative Transmission Ultrasound Research Shows Better Performance than Mammography

In Clinical Trials by Barbara Jacoby

From: PR Newswire First-in-class, first-in-human study compares new breast imaging modality to digital mammography QT Imaging™, developers of the FDA-cleared QTscan®, has completed a first-in-class and first-in-human study of transmission ultrasound as a new imaging technology for breast health screening. The recently published study in Academic Radiology found that, compared to full-field digital mammography (FFDM), transmission ultrasound showed increased sensitivity, …

View Post

New breast cancer drug shows promise, boosts the body’s ability to destroy tumors

In Clinical Trials by Barbara Jacoby

By: Study Finds From: studyfinds.org A signaling pathway in the body that helps fight off infections may also hold the key to a breakthrough in breast cancer research. Researchers from the University of North Carolina say activating this path can allow genetically engineered cells destroy breast cancer tumors in mice. Their study finds this immunotherapy activates the “STING” pathway, an …

View Post

Alpha-TEA helps with breast cancer

In Clinical Trials by Barbara Jacoby

By: Christina Burkhart From: abc12.com One in eight women will be diagnosed with breast cancer at some point in her lifetime. One in four of those breast cancer diagnosis will be HER-2-positive. It’s an aggressive form of breast cancer and is more likely to recur than HER2-negative breast cancer. Now a new trial is underway to stop this cancer in …

View Post

Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study

In Clinical Trials by Barbara Jacoby

From: docwirenews.com ABSTRACT Breast-conserving therapy was once a contraindication in young breast cancer patients (aged ≤40 years). Emerging studies suggest that breast-conserving therapy and mastectomy could achieve similar prognosis in this population. However, the effect of molecular subtype disparity on surgical strategy in these patients remains unclear. Data from 8656 young patients (aged ≤40 years) diagnosed with invasive breast cancer …

View Post

Evelo Biosciences, Inc. Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Evelo Biosciences, Inc. From: globenewswire.com –EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503– –Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product candidates to activate systemic immunity– Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine …

View Post

GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers

In Clinical Trials by Barbara Jacoby

Source: GT Biopharma, Inc. From: prnewswire.com GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE™) technology platform is pleased to announce the filing of U.S. and international patent applications, and the initiation of clinical development of TriKE™ therapy for the treatment of HER2+, HER3+ and HER2+/HER3+ heterodimer …

View Post

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Gina Mauro From: onclive.com Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented during the virtual 2020 San Antonio Breast Cancer Symposium.1,2 At the 9-mg and 18-mg doses of enobosarm, the 6-month clinical benefit rate (CBR) …

View Post

Discovery about how cancer cells evade immune defenses inspires new treatment approach

In Clinical Trials by Barbara Jacoby

Source: Memorial Sloan Kettering Cancer Center From: eurekalert.org Cancer cells are known for spreading genetic chaos. As cancer cells divide, DNA segments and even whole chromosomes can be duplicated, mutated, or lost altogether. This is called chromosomal instability, and scientists at Memorial Sloan Kettering have learned that it is associated with cancer’s aggressiveness. The more unstable chromosomes are, the more …